{"id":"cyclophosphomide","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00478452","NCT01929811","NCT00157196","NCT06855810","NCT01995331","NCT02531308","NCT06882057","NCT05366062","NCT01852435","NCT02676622"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"cyclophosphomide","companyId":"shanghai-jiao-tong-university-school-of-medicine","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Shanghai Jiao Tong University School of Medicine","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"cyclophosphomide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00478452","phase":"Phase 1","title":"Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Car","status":"COMPLETED","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":14,"indication":"Ovarian Cancer, Fallopian Tube Cancer","completionDate":"2008-08"},{"nctId":"NCT01929811","phase":"Phase 2","title":"Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer：A Prospective, Randomized Trial","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","isPivotal":false,"enrollment":92,"indication":"pCR Rate, BCT Rate","completionDate":"2020-06"},{"nctId":"NCT00157196","phase":"Phase 2","title":"A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","isPivotal":false,"enrollment":22,"indication":"Carcinoma, Non-Small-Cell Lung, Lung Neoplasms","completionDate":"2012-04"},{"nctId":"NCT06855810","phase":"Phase 2","title":"Chinese Children's Cancer Group T-cell Acute Lymphoblastic Leukemia -2025 Project","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","isPivotal":true,"enrollment":610,"indication":"Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic","completionDate":"2031-06"},{"nctId":"NCT01995331","phase":"Phase 4","title":"Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia","status":"UNKNOWN","sponsor":"Xiaofan Zhu","isPivotal":false,"enrollment":30,"indication":"Aplastic Anemia","completionDate":"2015-03"},{"nctId":"NCT02531308","phase":"Phase 2","title":"A Phase ll Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (RM-CHOP) for Previously Untreated Aggressive Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Rush University Medical Center","isPivotal":false,"enrollment":5,"indication":"Diffuse Large B-Cell Lymphoma","completionDate":"2016-07"},{"nctId":"NCT06882057","phase":"Phase 2","title":"Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed Low Risk Childhood B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","isPivotal":true,"enrollment":3000,"indication":"Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic","completionDate":"2033-06"},{"nctId":"NCT05366062","phase":"Phase 2","title":"Phase II Clinical Trial to Assess the Efficacy of ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab in Patients Who Have Failed ","status":"NOT_YET_RECRUITING","sponsor":"Epitopoietic Research Corporation","isPivotal":false,"enrollment":28,"indication":"Glioma, Malignant","completionDate":"2026-07-31"},{"nctId":"NCT01852435","phase":"Phase 3","title":"A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Gra","status":"UNKNOWN","sponsor":"Ruijin Hospital","isPivotal":true,"enrollment":648,"indication":"Diffuse Large B-cell Lymphoma, Follicular Lymphoma Grade 3B","completionDate":"2018-02"},{"nctId":"NCT02676622","phase":"Phase 2","title":"A Pilot Study of Autologous Hematopoietic Stem Cell Transplantation With Post-Transplant Ultra Low-Dose IL-2 for Refractory Crohn's Disease","status":"WITHDRAWN","sponsor":"Nationwide Children's Hospital","isPivotal":false,"enrollment":0,"indication":"Crohn's Disease","completionDate":"2013-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}